Navigation Links
New Study Shows that Genetic Information from Prostate Needle Biopsy May Be Used to Predict Tumor Aggressiveness
Date:3/15/2016

SAN DIEGO, March 15, 2016 /PRNewswire/ -- GenomeDx Biosciences today announced results from a new study which demonstrates the ability to measure and evaluate biomarkers from RNA expression data obtained from prostate needle biopsies. The data demonstrate a high concordance in the genomic signatures between needle biopsy samples and post-prostatectomy tissue samples, providing preliminary evidence that the Decipher score may be predictive of disease progression following biopsy as well as following prostate surgery.

The results, published in the May 2016 issue of Journal of Molecular Diagnostics, and currently available online ahead of print, provide important findings about the feasibility of the Decipher Prostate Cancer Classifier test to obtain transcriptome-wide RNA expression data and to measure and evaluate prognostic classifiers in diagnostic prostate needle biopsies. The Decipher Prostate Cancer Classifier test used in the study, Decipher Biopsy, yielded genomic data from biopsy and surgical tissues of comparable quality. These data indicate that a sufficient amount of RNA can be consistently and successfully derived from the limited tumor tissue in biopsy cores, despite variation in the way biopsy cores are obtained from multiple institutes. The research was conducted by GenomeDx and its collaborators from Cedars Sinai Medical Center, University of California, San Francisco, and University Health Network, Toronto.

This study further supports findings of a study recently published in Urology (Klein et ‪al. Urology 2016) in validating and demonstrating the clinical utility of Decipher Biopsy in diagnostic needle biopsies.

"More than 800,000 men undergo prostate biopsy annually in the United States to identify prostate cancer, and this study increases confidence that reliable, quality genomic information can be obtained for those biopsies to better classify patient risk," said Jeffry Simko, Ph.D., M.D., Professor of Clinical Pathology at the University of California, San Francisco. "Genomic biomarkers used by Decipher may help overcome current challenges of tumor heterogeneity and variability in staging of disease. This study demonstrates that the Decipher score may be predictive of disease progression in diagnostic prostate needle biopsies and warrants a larger, adequately powered study to validate this observation."

The study compared analysis of a total of 158 samples from 33 men, including pre-operative needle core biopsies and tissues obtained from radical prostatectomy. Notably, researchers identified that 95 percent of transcriptomic features expressed in surgical samples were expressed in pre-surgery biopsy samples with a high expression correlation (r=0.96). The expression signature pattern yielded by Decipher Biopsy showed a high degree of correlation between the two sample types (r=0.70) providing strong evidence of the utility of Decipher Biopsy in prostate needle biopsies.

About Decipher® Prostate Cancer Classifier Tests
Our Decipher Prostate Cancer Classifier tests are currently comprised of Decipher Biopsy and Decipher Post-Op. These commercially available genomic tests provide an assessment of tumor aggressiveness based on the patient's unique genomic profile. Decipher Biopsy is indicated for men after biopsy diagnosis and Decipher Post-Op is indicated for men after prostate removal surgery. The Decipher tests are used by physicians to stratify patients into more accurate risk groups to better determine which patients will likely benefit from additional treatment and which will not, thereby enabling improved decision-making and helping low-risk patients avoid unnecessary treatments that have serious adverse side effects and result in unnecessary costs to the healthcare system. Studies of thousands of patients from leading cancer centers, published in multiple peer-reviewed journals, demonstrate that the Decipher tests can more accurately predict disease aggressiveness than traditional clinical measures, such as PSA and Gleason score. Decipher Post-Op is covered by Medicare and by a number of private payors and preferred provider organizations representing, together with Medicare, about 70% of the approximately 66 million adult men in the United States age 40 or older who are at increased risk of being diagnosed with prostate cancer.

Learn more at www.DecipherTest.com

About Decipher GRID™
Our Decipher Genomics Resource Information Database (Decipher GRID) is a genomic data sharing platform that provides a foundation for open and interactive research collaboration and knowledge creation. Decipher GRID is a rapidly growing database that contains genomic profiles of thousands of patients, and constitutes what we believe to be the world's largest shared, clinically-annotated genomic expression database in urologic oncology and one of the world's largest global RNA expression databases utilizing cloud-based analytics. We believe Decipher GRID gives rise to new opportunities for information technology-enabled genomic solutions and enables more rapid discovery, development, commercialization and adoption of existing and new products. Through Decipher GRID, GenomeDx is building a suite of genomic tests to assist physicians and patients with clinical decision-making from disease screening through late-stage therapy.    

Learn more at www.DecipherGRID.com

About GenomeDx Biosciences
GenomeDx Biosciences uses the power of collaborative genomics to transform the management and treatment of cancer patients. GenomeDx has built Decipher GRID, a large genomics database in urologic oncology that provides a foundation for open and interactive research collaboration and knowledge creation. Using Decipher GRID to analyze vast amounts of genomic data, GenomeDx develops and commercializes proprietary clinical tests that provide more accurate and useful diagnostic information than both traditional diagnostic tools and existing genomic tests. GenomeDx's Decipher Post-Op and Decipher Biopsy are commercially available prostate cancer genomic tests that provide an assessment of tumor aggressiveness based on a patient's unique genomic profile. GenomeDx is based in San Diego, California and Vancouver, British Columbia.

Learn more at www.GenomeDx.com

Media Contact:
Ian Stone
Canale Communications
619-849-5388
ian@canalecomm.com

 


'/>"/>
SOURCE GenomeDx Biosciences
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. AcelRx Pharmaceuticals Advances ARX-04 into Extension Phase of Open-Label Phase 3 Emergency Room Study
2. Quark Pharmaceuticals Doses First Patients in Two Pivotal Phase III Studies and One Phase II Study of RNAi-Based Therapeutics for Kidney and Eye Indications
3. Eiger Announces Completion of Enrollment of Phase 2 LOWR HDV - 4 (LOnafarnib With Ritonavir in Hepatitis Delta Virus - 4) Study at Hannover Medical School
4. Study Highlights Best Practices in Globalizing Medical Science Liaison Programs
5. Regeneron and Sanofi Announce Topline Results of Phase 3 Monotherapy Study Demonstrating Superiority of Sarilumab vs. Adalimumab in Patients with Active Rheumatoid Arthritis
6. BioElectronics Invited to Present Chronic Pain Patient Observation Study at the British Pain Society Congress
7. Tobira Therapeutics Announces Publication of CENTAUR Phase 2b Study Design and Rationale in Contemporary Clinical Trials
8. Inari Medical Announces IDE Approval To Study The FlowTriever System For The Treatment Of Pulmonary Embolism
9. Stealth BioTherapeutics Initiates Phase 2 Clinical Study Of Elamipretide In Fuchs Corneal Endothelial Dystrophy
10. Celsion Corporation Announces Launch of the OPTIMA Study in China
11. Corvia Medical Receives IDE Approval For REDUCE LAP-HF I Clinical Study & Announces Agreement With Strategic Partner For Exclusive Option To Purchase Company
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2019)... Pa. (PRWEB) , ... June 19, 2019 , ... ... nuclear receptor and in vitro toxicology testing solutions, announced the addition of the ... kit expands INDIGO’s existing in vitro toxicology offerings and allows researchers to perform ...
(Date:6/18/2019)... ... June 18, 2019 , ... MY ... W Olympic Blvd Suite 350 Los Angeles, CA, 90064, bringing holistic solutions to ... , MY Education Guru has created individual programs to assist students who have ...
(Date:6/18/2019)... ... June 18, 2019 , ... Officials with American Physician ... are pleased to announce the acquisition of Leading Edge Medical Associates (LEMA), a ... physicians and 9 advanced practice clinicians care for 115,000 emergency department patients annually ...
Breaking Medicine Technology:
(Date:6/14/2019)... ... ... reviewed and approved providers for May 2019. , FL TOP DOCS INCLUDE: , BARIATRIC MEDICINE/SURGERY, ... Dr. Debbie Berlin , CARDIOLOGY, Dr. Nirat Beohar ... Dr. Yamilet Tirado , DERMATOLOGY, Dr. B. Jennifer Berkes ...
(Date:6/13/2019)... PETERSBURG, Fla. (PRWEB) , ... June 13, 2019 ... ... and research company today announced that it has signed a memorandum of understanding ... (API) for its drug product MMJ-001 and MMJ-002. , MMJ BioPharma Cultivation will ...
(Date:6/13/2019)... ... 13, 2019 , ... In Partnership with the Smiles for Everyone Foundation ... at its Mesquite, TX office on July 13th. , Dental services provided include same-day ... extractions . For more information, please visit the Monarch Dental website . , ...
(Date:6/13/2019)... ... June 13, 2019 , ... The ... present the second annual Women|Future Conference and the advisory board that ... better position themselves and their organizations in tomorrow's marketplace. , The mission of ...
(Date:6/13/2019)... ... ... Clinical Ink , a global clinical trial technology company that is ... chief business officer at Clinical Ink, has been invited to be a panelist in ... July 1, 2019, in Washington, D.C. The workshop, convened under a cooperative agreement with ...
Breaking Medicine News(10 mins):